{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T02:03:53Z","timestamp":1783649033624,"version":"3.55.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T00:00:00Z","timestamp":1695081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Purpose-Immunotherapy has revolutionized\u00a0cancer\u00a0therapy, becoming the standard\u00a0of\u00a0care for various malignancy treatments. Human immunodeficiency virus (HIV) patients, however, are an underserved group with limited access to clinical trials and cancer therapy. This study was to evaluate the safety and efficacy of programmed cell death 1 (PD - 1) inhibitors in patients with advanced cancer and HIV\/acquired immunodeficiency syndrome (AIDS). Methods and Materials-We performed a prospective, open-label, nonrandomized, phase 1 single center study. Patients with advanced cancer and HIV\/AIDS received the treatment of PD - 1 inhibitors (camrelizumab, 200 mg, administered intravenously every 3 weeks), along with combination antiretroviral therapy (cART) for HIV. Results-Sixteen participants (12 men and 4 women; median age, 46.5 (29 - 78) years) were enrolled; 1 had non - Hodgkin lymphoma (NHL), and 15 had non - AIDS - defining cancers. Safety was observed over 130 cycles of treatment with camrelizumab. Most treatment-emergent adverse events at least possibly attributed to camrelizumab were grade 1 or 2, including reactive cutaneous capillary endothelial proliferation (RCCEP) (9 participants), hearing loss (1 participant), hypophysitis (1 participant). 3 participants experienced hemorrhage due to poor performance status. HIV was controlled in all participants. Best tumor responses included 3 complete response, 5 partial response, 2 stable disease, and 6 progressive disease. The 2 years progression-free survival (PFS) was 67.0% (95% CI: -0.05, 0.00) and overall survival (OS) was 55.3% (95% CI: -0.05, 0.01) for the 16 patients who had received camrelizumab. Conclusions-This study demonstrates that camrelizumab treatment in patients with advanced cancers and HIV\/AIDS was feasible and the clinical outcomes were acceptable.<\/jats:p>","DOI":"10.3389\/fonc.2023.1248790","type":"journal-article","created":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T05:51:11Z","timestamp":1695189071000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["The safety and efficacy of PD-1 inhibitors in patients with advanced cancers and HIV\/AIDS in China"],"prefix":"10.3389","volume":"13","author":[{"given":"Yu","family":"Xiong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingzheng","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajun","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,9,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s11904-019-00478-x","article-title":"Optimizing treatment for adults with HIV\/AIDS in China: successes over two decades and remaining challenges","volume":"17","author":"Cao","year":"2020","journal-title":"Curr HIV\/AIDS Rep"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1056\/NEJMra1615896","article-title":"HIV-associated cancers and related diseases","volume":"378","author":"Yarchoan","year":"2018","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1097\/COH.0000000000000334","article-title":"Combination antiretroviral therapy and cancer risk","volume":"12","author":"Borges","year":"2017","journal-title":"Curr Opin HIV AIDS"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.1016\/S2352-3018(18)30295-9","article-title":"Contributions of traditional and HIV-related risk factors on non-AIDS-defining cancer, myocardial infarction, and end-stage liver and renal diseases in adults with HIV in the USA and Canada: a collaboration of cohort studies","volume":"6","author":"Althoff","year":"2019","journal-title":"Lancet HIV."},{"key":"B5","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1002\/cncr.31838","article-title":"Cancer disparities in people with HIV: A systematic review of screening for non-AIDS-defining Malignancies","volume":"125","author":"Corrigan","year":"2019","journal-title":"Cancer."},{"key":"B6","doi-asserted-by":"publisher","first-page":"768","DOI":"10.7326\/M20-5226","article-title":"Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy: a multinational prospective cohort study","volume":"174","author":"Chammartin","year":"2021","journal-title":"Ann Intern Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25219","article-title":"Trends in mortality among ART-treated HIV-infected adults in the Asia-Pacific region between 1999 and 2017: results from the treat Asia HIV observational database (TAHOD) and Australian HIV observational database (AHOD) of IeDEA Asia-Pacific","volume":"22","author":"Jung","year":"2019","journal-title":"J Int AIDS Soc"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abl3836","article-title":"Pembrolizumab induces HIV latency reversal in people living with HIV and cancer on antiretroviral therapy","volume":"14","author":"Uldrick","year":"2022","journal-title":"Sci Transl Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s40264-018-0774-8","article-title":"Safety and tolerability of immune checkpoint inhibitors (PD-1 and PD-L1) in cancer","volume":"42","author":"Baraibar","year":"2019","journal-title":"Drug Saf."},{"key":"B10","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/S1470-2045(20)30110-8","article-title":"Camrelizumab versus investigator\u2019s choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study","volume":"21","author":"Huang","year":"2020","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S1470-2045(20)30011-5","article-title":"Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial","volume":"21","author":"Qin","year":"2020","journal-title":"Lancet Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S2213-2600(20)30365-9","article-title":"Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non- squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial","volume":"9","author":"Zhou","year":"2021","journal-title":"Lancet Respir Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"102836","DOI":"10.1016\/j.critrevonc.2019.102836","article-title":"Treating cancer with immunotherapy in HIV-positive patients: A challenging reality","volume":"145","author":"Guaitoli","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.jtho.2018.03.031","article-title":"Safety and efficacy of PD-1 inhibitors among HIV-positive patients with non-small cell lung cancer","volume":"13","author":"Ostios-Garcia","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"F13","DOI":"10.1097\/QAD.0000000000002298","article-title":"Immunotherapy for cancer in people living with HIV: safety with an efficacy signal from the series in real life experience","volume":"33","author":"Spano","year":"2019","journal-title":"Aids"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1097\/QAD.0000000000002919","article-title":"The impact of immune checkpoint therapy on the latent reservoir in HIV-infected individuals with cancer on antiretroviral therapy","volume":"35","author":"Lau","year":"2021","journal-title":"Aids."},{"key":"B17","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","article-title":"Refinement of the Lugano classification lymphoma response criteria in the era of immunomodulatory therapy","volume":"128","author":"Cheson","year":"2016","journal-title":"Blood."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1001\/jamaoncol.2019.2244","article-title":"Assessment of the safety of pembrolizumab in patients with HIV and advanced cancer - a phase 1 study","volume":"5","author":"Uldrick","year":"2019","journal-title":"JAMA Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1001\/jamaoncol.2020.0465","article-title":"Assessment of the feasibility and safety of durvalumab for treatment of solid tumors in patients with HIV-1 Infection: the phase 2 DURVAST study","volume":"6","author":"Gonzalez-Cao","year":"2020","journal-title":"JAMA Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1001\/jamaoncol.2018.6737","article-title":"Safety and efficacy of immune checkpoint inhibitor therapy in Patients with HIV infection and advanced-stage cancer: a systematic review","volume":"5","author":"Cook","year":"2019","journal-title":"JAMA Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s12094-018-1981-6","article-title":"Cancer immunotherapy of patients with HIV infection","volume":"21","author":"Gonzalez-Cao","year":"2019","journal-title":"Clin Translat Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"108580","DOI":"10.1016\/j.intimp.2022.108580","article-title":"Exploring the application of immunotherapy against HIV infection in the setting of Malignancy: A detailed review article","volume":"105","author":"Makuku","year":"2022","journal-title":"Int Immunopharmacol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.ejca.2019.11.019","article-title":"CheckMate 171: a phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS2 and elderly population","volume":"127","author":"Felip","year":"2020","journal-title":"Eur J Cancer."},{"key":"B25","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/S2213-2600(20)30033-3","article-title":"Pembrolizumab in patients with non-smallcell lung cancer of performans status 2 (PePS2): a single arm, phase 2 trial","volume":"8","author":"Middleton","year":"2020","journal-title":"Lancet Respir Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.jtho.2019.05.010","article-title":"Safety, efficacy, and patient-reported health-related quality of life and symptom burden with nivolumab in patients with advanced non-small cell lung cancer, including patients aged 70 years or older or with poor performance status (CheckMate 153)","volume":"14","author":"Spigel","year":"2019","journal-title":"J Thorac Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"S214","DOI":"10.1016\/j.jtho.2019.08.424","article-title":"CheckMate 817: first-line nivolumab + ipilimumab in patients with ECOG PS 2 and other special populations with advanced NSCLC","volume":"14","author":"Barlesi","year":"2019","journal-title":"J Thorac Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000019013","article-title":"Safety and efficacy of immune checkpoint inhibitors in patients with HBV\/HCV infection and advanced-stage cancer: a systematic review","volume":"99","author":"Pu","year":"2020","journal-title":"Medicine."},{"key":"B29","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.lungcan.2020.04.025","article-title":"Ongoing challenges of using immunotherapy in special populations: poor performance status patients, elderly patients, and people living with HIV","volume":"145","author":"Gounant","year":"2020","journal-title":"Lung Cancer."},{"key":"B30","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1053\/j.seminoncol.2018.08.007","article-title":"FDA analyses of survival in older adults with metastatic non-small cell lung cancer in controlled trials of PD-1\/PD-L1 blocking antibodies","volume":"45","author":"Marur","year":"2018","journal-title":"Semin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1248790\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T05:51:12Z","timestamp":1695189072000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1248790\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,19]]},"references-count":30,"alternative-id":["10.3389\/fonc.2023.1248790"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1248790","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,19]]},"article-number":"1248790"}}